128 results about "Bone resorption" patented technology

The invention relates to the technical field of oral implantation guidance, and provides a digital false tooth mounting and positioning device based on three-dimensional scanning and a method thereof. The method comprises the following steps: scanning the oral cavity of a patient through an oral cavity scanner to generate a three-dimensional oral cavity digital model; generating a virtual implant of the patient and corresponding initial implantation parameters based on the three-dimensional oral cavity digital model through a SegFormer segmentation network; based on historical operation data, initial implantation parameters, bone density, patient attributes and occlusal force parameters, a long sequence prediction network is adopted to predict the position offset and bone resorption degree of the virtual implant after osseointegration through a segmented attention mechanism and a network memory cache mechanism, and optimal implantation parameters are obtained; and pushing a visual dynamic model containing the candidate positioning strategy to the user based on the optimal implantation parameter, driving an oral cavity model printer to obtain an implantation guide plate model and an oral cavity environment model, assisting the user in verifying the installation effect of the candidate positioning strategy, and improving the accuracy of false tooth installation and positioning.

The invention belongs to the field of medicines, and particularly relates to application of a new target NCSTN for regulating and controlling bone metabolism and an agonist of the new target NCSTN in preparation of a medicine for preventing or treating osteoporosis. The invention aims to provide a new target NCSTN for regulating and controlling bone metabolism and application of the new target NCSTN in promoting osteogenic activity, inhibiting osteoclast activity and treating osteoporosis. According to the invention, the mechanism of the NCSTN agonist for treating osteoporosis is found for the first time, and the NCSTN agonist has the effects of inhibiting osteoclast maturation and differentiation and promoting osteoblast bone formation function. The mechanism is greatly different from the previously reported mechanism of singly inhibiting bone resorption or singly promoting bone formation, and the osteoporosis treatment which simultaneously acts on bone resorption and bone formation can greatly reduce the adverse reaction of the body to the medicine.

The invention relates to the technical field of biological medicines, in particular to rhizoma drynariae extracellular vesicles for treating periodontitis by targeting macrophage ETS2 genes as well as a preparation method and application of the rhizoma drynariae extracellular vesicles. The extracellular vesicles are creatively extracted from the traditional Chinese medicine rhizoma drynariae by combining a differential ultracentrifugation method with a sucrose density gradient centrifugation method, the functions of the extracellular vesicles are studied, and it is found that the extracellular vesicles can effectively slow down alveolar bone resorption in a periodontitis state and reduce periodontal soft tissue inflammation and have a good treatment effect on periodontitis. It is found for the first time that the rhizoma drynariae extracellular vesicles can reduce the inflammatory ability of macrophages in an inflammatory state and can reduce expression of proinflammatory factors TNF-alpha and IL-6. The invention has important scientific research value and clinical significance for further development and application of various traditional Chinese medicine plant extracellular vesicles including rhizoma drynariae extracellular vesicles.

The invention discloses injectable double-drug delivery hydrogel and a preparation method thereof, and belongs to the technical field of biomedical materials. According to the method, two nano microspheres with different charges are respectively prepared by utilizing the characteristics of A-type gelatin and B-type gelatin, a negatively charged medicine EGCG is specifically carried by the positively charged A-type gelatin, and a positively charged medicine SAG is carried by the negatively charged B-type gelatin microsphere; and finally, mixing the two gelatin drug-loaded microspheres into a material taking gelatin and zirconium ions as a substrate to form the composite hydrogel. The hydrogel realizes immune regulation and osteogenesis regulation, also realizes long-acting release of the two drugs, effectively solves the problems of bone resorption, difficulty in healing and the like of host tissues through synergistic regulation of inflammation and mobilization of osteogenesis genes, realizes personalized treatment, and improves the clinical treatment effect and efficiency.

The invention provides a milk protein peptide which takes milk protein as a raw material and has the effects of promoting calcium absorption and improving bone health and application of the milk protein peptide. Specifically, milk protein peptide sequences, including YGGVSL and SQRY, are screened by adopting enzymolysis, sequence identification and molecular docking methods. The milk protein peptide is proved to have high calcium transport promoting capacity in the in-vitro intervention of Caco-2 cells, and the milk protein peptide is proved to have the capacity of promoting osteogenesis and inhibiting bone resorption in the in-vitro intervention of MC3T3-E1 mouse embryo osteoblasts. In animal experiments, by increasing the content of blood calcium and bone calcium, reducing the content of excrement calcium, improving mRNA expression of calcium ion channel protein, calcium binding protein and peptide transporter in intestinal tracts, enhancing the efficiency of calcium entering blood, promoting osteogenesis and inhibiting bone resorption, the milk protein peptide is comprehensively proved to have the capabilities of improving calcium resorption of organisms and improving bone health. The milk protein peptide has both functionality and nutrition, and has a wide application prospect in the aspect of bone health.

The invention relates to the technical field of oral cavities, and discloses an alveolar bone resorption degree detection method, device and equipment and a medium, oral cavity image data of a patient is obtained, and tooth jaw segmentation data extraction is performed on the oral cavity image data to obtain tooth jaw segmentation data; performing three-dimensional space morphological feature analysis on tooth segmentation data in the tooth jaw segmentation data to obtain tooth coordinate azimuth information; calculating periodontal measurement surface information according to the tooth coordinate azimuth information; extracting enamel boundary line data and alveolar bone boundary line data in the dental jaw segmentation data; calculating an alveolar bone resorption degree result according to the enamel boundary line data, the alveolar bone boundary line data and the periodontal measurement surface information; the alveolar bone resorption degree result is calculated through the boundary line data and the measurement surface information, and the accuracy of the result is improved while the resorption degree is accurately quantified.

The application discloses a preparation method of a customized porous TMJ prosthesis deposited with europium-doped black phosphorus nanosheets, and comprises the following steps: S1, CBCT is used to shoot medical image data, which is imported into Mimics software to reconstruct a model, the reconstructed model is imported into Geomagic software to simulate bone cutting, and a craniofacial model STL file is obtained; S2, TMJ prosthesis customization design is performed on the craniofacial model STL file; S3, SLM printing technology is adopted to perform 3D printing on the customized TMJ prosthesis model, and a prosthesis entity is obtained; and S4, a polydopamine europium-doped black phosphorus nanosheet surface coating is constructed on the porous region of the prosthesis entity model. The application realizes product customization by adopting computer-aided design and three-dimensional printing technology; the europium-doped black phosphorus nanosheet coating is constructed on the porous region of the prosthesis, the mandibular stump and the buccal region are promoted to grow into bone, the traditional "two-dimensional fixation" is changed into "three-dimensional fixation", and the limitation of screw loosening, falling off and bone resorption is got rid of.

The invention relates to the technical field of biomedicine, and particularly provides a mouse model capable of being inductively combined with epithelial cell specific ablation and application of the mouse model. The method comprises the following steps: inserting a '3xFLAG-P2A-CreERT2 'functional frame at a fixed point at a termination codon of a mouse Odam gene, so as to obtain an OdamCreERT2 mouse. The expression specificity of the Odam gene in binding epithelium is verified by a mouse obtained by copulating with a ROSA26mT / mG reporter gene mouse; mice obtained by mating with ROSA26DTA cell ablation mice reveal the indispensable function of binding epithelium in maintaining periodontal barrier and preventing bone resorption. The model retains endogenous Odam expression and functions, supports protein dynamic tracing and space-time specific gene manipulation, and is suitable for researching the effect of binding epithelium in periodontal barrier integrity and alveolar bone resorption prevention.

This invention discloses a histone-derived peptide nanoparticle targeting the degradation of cytoplasmic cGAS, its preparation method, and its applications. The invention is characterized by: dissolving a peptide complex in phosphate buffer, sonicating, allowing it to self-assemble at room temperature to form nanoparticles, and purifying by centrifugation to obtain histone-derived peptide nanoparticles A4@CMA NPs targeting the degradation of cytoplasmic cGAS. These nanoparticles (A4@CMA NPs) can target and bind to cytoplasmic cGAS, mediating its degradation, blocking the activation of the cGAS-STING pathway, effectively reducing periodontal inflammation and alveolar bone resorption, and providing a new strategy for the treatment of periodontitis.

The present invention addresses the problem of providing an osteogenesis promoting agent and a pharmaceutical composition for preventing or treating a disease or a symptom involving bone defect, osteogenesis imperfecta, osteogenesis disorder, and / or bone hyperresorption.　The problem is solved by: a compound represented by general formula (I), a salt thereof, or a prodrug thereof; and a composition and a pharmaceutical composition containing the same.

The present application relates to a kind of RANKL / NLRP3 dual-target inhibitor and its preparation method and application, belong to the field of pharmaceutical chemistry and biomedical technology.The indole compound, its optical isomer, pharmaceutically acceptable salt and hydrate provided by the present application have RANKL and NLRP3 dual-target inhibition activity, can be inhibited by inhibiting RANKL-RANK interaction, and inhibit inflammasome NLRP3 activity, regulate RANKL activity in osteoclast precursor cell, inhibit the formation of osteoclast, thereby reduce bone resorption, and improve the inflammatory response caused by rheumatoid arthritis, is expected to play the prevention and treatment of bone metabolic disease.

The invention discloses a method for preparing a phosphorylated salmon collagen peptide-calcium chelate by taking salmon collagen peptide as a raw material, preparing high-calcium binding active peptide (P-CP) through phosphorylation modification and chelating the high-calcium binding active peptide with calcium ions. The method comprises the following steps: (1) enzymolysis preparation of salmon bone collagen; (2) phosphorylation modification of a peptide fragment mediated by sodium tripolyphosphate; and (3) optimizing a calcium ion chelation process. The chelating rate of the obtained P-CP-Ca calcium reaches 91.21%, and structural characterization proves that a phosphate group (PO4 < 2->) is combined with calcium ions through ionic bonds. Animal experiments show that P-CP-Ca can significantly improve the serum calcium level of a calcium-deficiency mouse (the H group recovers to a normal range), reduce the activity of a bone resorption marker TRAP (Target Related Amplified Protein) (which is 25.4% lower than that of a model group), and improve the bone trabecula microstructure (the bone mineral density is improved by 32.7%). The invention provides a new technology for valuable utilization of fishery by-products and development of functional calcium supplements.

The present application relates to the technical field of medicine, and more particularly to the application of beta-hydroxybutyric acid in the preparation of a drug for preventing and / or treating osteoporosis, including postmenopausal osteoporosis due to estrogen deficiency and diabetic osteoporosis, wherein the concentration of the beta-hydroxybutyric acid is 150 mM, the application of beta-hydroxybutyric acid in the preparation of a drug for inhibiting the differentiation of osteoclasts or inhibiting the formation of osteoclasts, wherein the beta-hydroxybutyric acid inhibits the differentiation of osteoclast precursor cells into osteoclasts, and the concentration of the beta-hydroxybutyric acid is 10 mM; the present application proves that beta-hydroxybutyric acid improves the bone microstructure of OVX mice and db / db mice, inhibits the differentiation of osteoclasts, and reduces bone resorption, thereby providing a new target for the prevention and treatment of osteoporosis.

A biocompatible 3D-printed scaffold is described. The scaffold includes a biocompatible polymer shaped to form a scaffold using 3D printing and a gallium compound. Methods of making 3D-printed scaffolds, and methods of using 3D-printed scaffolds to inhibit bone resorption are also described.

This invention provides an interbody fusion device and its preparation method, comprising: metal endplates symmetrically arranged vertically, with a mesh structure on the surface of the metal endplates, the mesh structure including: a bone mesh on the outer surface of the metal endplates, a coupling mesh on the inner surface of the metal endplates, a metal separator layer fixedly disposed between the bone mesh and the coupling mesh, and a linkage locking seat disposed on the inner surface of the metal endplates; a cable passing through the linkage locking seat on the inner surface of the aforementioned metal endplates; a polymer matrix fixed between the aforementioned pair of metal endplates by the aforementioned shear-resistant structure; a bone graft cavity, which is a cavity jointly formed by the metal endplates and the polymer matrix; and a positioning hole penetrating the aforementioned polymer matrix. This application addresses the technical problems that, with prolonged implantation time, complications such as displacement, coating peeling, settlement, stress shielding, bone resorption in adjacent areas, and delayed inflammatory reactions often occur.

The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to a traditional Chinese medicine preparation for strengthening bones and tendons and improving osteoporosis and a preparation method thereof. The traditional Chinese medicine preparation is prepared from the following raw material medicines in parts by weight: 25 to 30 parts of bovine bone, 15 to 20 parts of penis cervi, 10 to 15 parts of fructus mali, 8 to 12 parts of fructus corni, 8 to 10 parts of radix angelicae sinensis, 8 to 12 parts of semen sojae germinatum, 8 to 10 parts of rhizoma dioscoreae, 5 to 10 parts of rhizoma polygonati and 5 to 10 parts of liquorice root. In the formula, bovine bone and penis et testis cervi are taken as monarch drugs, malaytea scallop fruit, dogwood and angelica sinensis are taken as ministerial drugs, semen sojae germinatum, Chinese yam and rhizoma polygonati are taken as adjuvant drugs, and liquorice is taken as a conductant drug. All the components of the traditional Chinese medicine preparation have a synergistic effect, and the purpose of treating osteoporosis is achieved by adjusting the levels of ALP, OC and TRACP-5b, improving bone metabolism, increasing bone mineral density and inhibiting bone resorption.

The present application belongs to the field of medicine, and particularly relates to a new target point NCSTN for regulating bone metabolism and application of an agonist of the target point in preparation of a medicine for preventing or treating osteoporosis. One object of the present application is to provide a new target point NCSTN for regulating bone metabolism and application of the target point in promoting osteogenic activity, inhibiting osteoclast activity and treating osteoporosis. The present application first discovers a mechanism of treating osteoporosis by using an agonist of NCSTN, and has the effect of inhibiting mature differentiation of osteoclasts and promoting bone formation function of osteoblasts. This is very different from the previously reported mechanism of single inhibition of bone resorption or single promotion of bone formation, and the treatment of osteoporosis by simultaneously acting on bone resorption and bone formation can greatly reduce adverse reactions of the body to the medicine.

This invention discloses an osteoporosis biomarker circRNA and its applications, belonging to the field of biotechnology. This invention demonstrates that circBBS9 and its human homologs are expressed at elevated levels in osteoporosis. Simultaneously, a siRNA capable of knocking down circBBS9 expression was designed. This invention demonstrates that miR-423-3p is a downstream target of circBBS9. circBBS9 expression rapidly increases during osteoclast multinucleation, and inhibiting circBBS9 does not affect the differentiation of osteoclast mononuclear precursors, but weakens osteoclast multinucleation levels and bone resorption capacity, increasing bone mineral density in osteoporotic mice. This proves that the siRNA prepared in this invention can be used as a drug for the prevention and treatment of osteoporosis.

The application provides a traditional Chinese medicine granule for improving osteoporosis and a preparation method and application thereof, and belongs to the technical field of medicines. Codonopsis pilosula, drynaria rhizome, epimedium and eucommia are subjected to deep eutectic solvent extraction, purification, and preparation of a traditional Chinese medicine extract, water extraction, dialysis and drying of pilose antler to prepare pilose antler protein peptide; water extraction and alcohol precipitation of cistanche to prepare cistanche polysaccharide; after modification of hydroxyapatite by citric acid, sodium dihydrogen phosphate and beta-cyclodextrin, the product is prepared by inclusion of calcium salt, alpha-cholecalciferol and vitamin D3, and then mixed with the traditional Chinese medicine extract, the pilose antler protein peptide and the cistanche polysaccharide to prepare the traditional Chinese medicine granule for improving osteoporosis. The prepared traditional Chinese medicine granule for improving osteoporosis can promote the synthesis of collagen and bone matrix protein, inhibit bone resorption, promote bone remodeling and enhance the activity of osteoblasts, and has a good improvement effect on osteoporosis, bone fracture and other symptoms, and has a wide application prospect.

A method for constructing a microfluidic bone organoid-on-chip can continuously observe the impacts of different external factors on a bone tissue structure based on the “ternary regulation theory” of bone angiogenesis-bone resorption-osteogenesis coupling. The method includes: (1) building a visual three-dimensional cell cultivation platform to continuously observe impacts of different external factors on a ternary regulation theory based on angiogenesis of osteoclast precursors, osteoblasts and osteoclasts, such that a user is allowed to directly observe interactions among various kinds of cells; (2) designing microfluidic channels in a chip to allow a reagent involved to present a concentration gradient distribution in the chip; and (3) adding three bioinks including osteoblasts, osteoclasts and vascular endothelial cells respectively, so as to reflect the three cell components individually, in pairs, and as a whole in the chip. An apparatus for constructing a microfluidic bone organoid-on-chip is further provided.

This invention discloses a benzylindole compound, its preparation method, and its application, relating to the field of pharmaceutical technology. The compound, as shown in formula (A), (B), or (C), or its prodrug, deuterated derivative, or pharmaceutically usable salt, is obtained by introducing different substituents at specific positions on the benzylindole core. This type of compound exhibits good catepsin K inhibitory activity and can effectively inhibit osteoclast bone resorption. The preparation method of this invention uses conventional chemical raw materials as starting materials and obtains the target compound through stepwise reactions such as condensation, cyclization, substitution, or acylation. Different types of compounds can share key intermediates. The synthetic route is scientifically designed, the reaction conditions are mild, the catalytic efficiency is high, and the product purification is simple, making it suitable for industrial-scale production.

The invention relates to application of 2, 2 ': 5', 2 ''-trithiophene-5-formaldehyde in preparation of medicines for treating osteoporosis, and belongs to the technical field of biological medicines. The application of 2, 2 ': 5', 2 ''-trithiophene-5-formaldehyde in preparation of the medicine for treating osteoporosis is found for the first time, and especially the excellent application of 2, 2 ': 5', 2 ''-trithiophene-5-formaldehyde in preparation of the medicine for treating osteoporosis of postmenopausal women is found. In the cell level, the 2, 2 ': 5', 2 ''-trithiophene-5-formaldehyde shows obvious osteogenesis promotion and adipogenesis inhibition activity. On the animal level, the 2, 2 ': 5', 2 ''-trithiophene-5-formaldehyde can significantly improve bone mass loss of mice with osteoporosis caused by OVX, and promotes bone formation while inhibiting bone resorption. The result shows that the 2, 2 ': 5', 2 ''-trithiophene-5-formaldehyde has a good osteoporosis treatment effect, provides a novel anti-osteoporosis medicine for clinic, and has a wide application prospect and a relatively high application value.

The application discloses a hydrogel composite material CMU-L.p-36@MeHA and a preparation method and application thereof, and belongs to the technical field of biotechnology.The hydrogel composite material CMU-L.p-36@MeHA disclosed by the application loads plant lactobacillus CMU-L.p-36 on a MeHA hydrogel carrier.The CMU-L.p-36@MeHA hydrogel disclosed by the application shows a good treatment effect on rat periodontitis by reducing alveolar bone absorption, reducing expression of inflammatory factor TNF-alpha, promoting ordered arrangement of collagen fibers and repairing periodontal tissues.

The invention provides application of wogonoside in preparation of a medicine for preventing and treating inflammatory osteolysis, and belongs to the technical field of bone disease treatment, wogonoside has an inhibiting effect on RANKL-induced osteoclast generation and bone resorption, and MAPK and NF-kB signal channels related to osteoclast differentiation are detected through WB and PCR experiments. The wogonoside has an inhibiting effect on osteoclast differentiation, bone resorption function and bone loss of LPS-induced inflammatory osteolysis mice, and the effect is possibly related to inhibition of RANKL-mediated ROS level and a downstream MAPK signal channel. Therefore, the invention possibly provides a new treatment thought for preventing inflammatory osteolysis diseases.

The application discloses a preparation method of a 3D printing hip joint stress relief heat treatment double-gradient bone support, and the method comprises the following steps: acquiring image data by performing three-dimensional scanning on a bone defect by means of a CT scanning device, designing the size and shape of a transplantable bone, designing a concave hexagonal support structure with gradient porosity by means of UG three-dimensional drawing software, and gradually transitioning from a Ti-35Nb-5Ta-7Zr alloy with good biocompatibility and a low elastic modulus to a Co-Cr-Mo alloy with good wear resistance and corrosion resistance, improving metallurgical incompatibility, obtaining better interface combination, minimizing bone resorption and aseptic loosening caused by wear, prolonging the service life of an implant, and performing annealing heat treatment on the functional support after printing to eliminate residual stress and depositing a HA coating to enhance cell activity.

The invention relates to an application of 5-selenoflavone serving as an Nrf2 activator in preparation of an anti-osteoporosis medicine. The Nrf2 activating agent is a 5-seleno flavone compound 5c, namely, 7-fluoro-2-(3-methyl phenyl)-5-(3-methyl phenyl seleno)-flavone 5c. According to the invention, it is found for the first time that the 5-selenoflavone compound 5c can directly form a non-covalent bond with Keap1Kelch domain to inhibit Keap1-Nrf2 protein-protein interaction, and the 5-selenoflavone compound 5c is a novel micromolecular Nrf2 activator. The Nrf2 activator has obvious anti-osteoporosis activity, can directly form a non-covalent bond with Keap1Kelch domain to inhibit Keap1-Nrf2 protein-protein interaction, activate Nrf2, inhibit ROS and inhibit MAPK and NF-kappa B signal channels, further effectively inhibits osteoclast differentiation and bone resorption activity thereof and inhibits in-vivo bone loss, can be used for preparing anti-osteoporosis drugs, and has broad application prospects. The invention provides a novel anti-osteoporosis medicine for clinic, and has better clinical application value and wide application prospect.

The application belongs to the field of treating blood vessel-bone coupling imbalance diseases in traditional Chinese medicine, and particularly relates to a composition for treating blood vessel-bone coupling imbalance diseases, a pharmaceutical preparation and application. Geniposide alone or in combination with crocin I can effectively reduce endothelial cell damage under pathological stimulation conditions, reduce the level of cell apoptosis and the degree of oxidative stress, improve the vascular endothelial function state, and can also significantly inhibit osteoclast differentiation, reduce the number of mature osteoclasts, and reduce bone resorption activity, thereby being conducive to restoring the dynamic balance between bone formation and bone resorption.

The invention discloses application of Crlf2 in preparation of a medicine for preventing, relieving and / or treating osteoporosis, and relates to the technical field of new application of medicines. According to the application of the Crlf2 in preparation of the medicine for preventing, relieving and / or treating the osteoporosis, the key regulation and control function of the Crlf2 in differentiation of bone tissue related cells and osteoporosis diseases is disclosed for the first time, and a new theoretical perspective is provided for pathogenesis of the osteoporosis; it is found that the Crlf 2 inhibitor (such as a specific antibody or a small molecule inhibitor) can be directly used for preparing the efficient and high-targeting anti-osteoporosis medicine, the limitation of existing treatment means (such as bisphosphonate medicine inhibiting bone resorption but not promoting bone formation) is broken through, and accurate intervention aiming at a specific signal channel is achieved.

The invention belongs to the technical field of biological medicine, and discloses an application of a Wip1 inhibitor in preparation of a medicine for treating osteoporosis, the Wip1 inhibitor comprises one of GSK2830371, CCT007093 and SL-176, and the Wip1 inhibitor realizes treatment of osteoporosis by inhibiting osteoclast differentiation and inhibiting osteoclast bone resorption function.

A compound, which can act as inhibitors of protein kinases, especially Class III RTKs such as FLT3, PDGFRα, c-KIT and / or CSF-1R kinases, for the treatments of diseases or disorders mediated by such kinases, has a structure of formula (I):or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a binder of a Proteolysis-Targeting Chimera (PROTAC) thereof. The compound can be used in the treatments of diseases or conditions mediated by FLT3, PDGFR, c-KIT, and / or CSF-1R kinases, or mediated by a mutant kinase of FLT3, PDGFR, c-KIT, and / or CSF-1R kinases. Such diseases or conditions may include cancers, autoimmune diseases, and bone resorptive diseases.